Document is current
Any future updates will be listed below
-
Authors
Haghshenas, Sadegheh
Foroutan, Aidin
Bhai, Pratibha
Levy, Michael A.
Relator, Raissa
Kerkhof, Jennifer https://orcid.org/0000-0003-1245-6606
McConkey, Haley
Skinner, Cindy D.
Caylor, Raymond C.
Tedder, Matthew L. https://orcid.org/0000-0003-0613-6702
Stevenson, Roger E. https://orcid.org/0000-0002-1806-6345
Sadikovic, Bekim https://orcid.org/0000-0001-6363-0016
Schwartz, Charles E. https://orcid.org/0000-0002-7770-1943
- License Information
-
More Information
Article History
Received: 7 February 2022
Revised: 24 January 2023
Accepted: 1 February 2023
First Online: 16 February 2023
Competing interests
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interest. CES was previously affiliated with GGC, which provides commercial diagnostic services using EpiSign. This study however, was initiated after his retirement from GGC in collaboration with BS. Some of the genome-wide data was generated at GGC on a research basis at the request of CES. Thus, it is not linked to the commercial diagnostic services at GGC.
: All of the samples and records were de-identified. The study protocol has been approved by the Western University Research Ethics Board (REB 106302), and the IRB of Self Regional Healthcare. Informed consent was obtained by physicians for use of the clinical information of the described patients.
